HOME >> BIOLOGY >> NEWS
Giant pandas have plenty of genetic diversity

Even though there are only about 1,000 giant pandas left, there is hope for this beloved endangered species. A comprehensive genetic analysis of three wild giant panda populations shows that they still have enough genetic diversity to recover.

"From a strictly genetic perspective, the giant panda species and the three populations look promising...they have retained a large amount of diversity in each population," say Lu Zhi of Peking University in Beijing, China, Stephen O'Brien of the Laboratory of Genomic Diversity at the National Cancer Institute in Frederick, Maryland, and their co-authors in the December issue of Conservation Biology.

Despite its status as the "poster animal" of endangered species, little is known about the remaining populations of giant pandas in the wild. Historically, giant pandas lived in forests from China to northern Burma and Vietnam, but extensive deforestation has restricted the species to six alpine forest fragments in the rugged mountain ranges along the Tibetan plateau in western China. Assisted by conservation organizations, the Chinese government has recently stepped up efforts to protect the pandas: since 1993 the number of reserves has more than doubled (from 14 to 33), and they are monitored and patrolled more frequently.

However, biologists estimate that the remaining giant pandas are divided into about 25 populations with fewer than 20 individuals each. Because small, isolated populations are more likely to die out, this increases the risk that the species will become extinc. Lu, O'Brien and their colleagues analyzed the genetic variation in giant pandas primarily from populations in three mountain ranges: one that is separated from the others by a 75-mile-wide valley (Qinling) and two that are adjacent (Minshan and Qionglai).

The researchers found that the giant panda has moderate genetic diversity compared other carnivores. "The giant pa
'"/>

Contact: Stephen O'Brien
obrien@ncifcrf.gov
301-846-1296
Society for Conservation Biology
30-Nov-2001


Page: 1 2

Related biology news :

1. Giant bloom fades, science continues
2. Scientist probes fossil oddity: Giant redwoods near North Pole
3. Giant icebergs, unprecedented ice conditions threaten Antarctic penguin colonies
4. From dolphins to the Giant Panda - chemistry at SeaWorld and the San Diego Zoo
5. Giant jellies invade Gulf of Mexico threatening shrimp fishery
6. Giant plant-eating dinosaur found; two cast skeletons to be unveiled
7. First Dinosaur Embryo Skin Discovered -- Unhatched Embryos Are First Ever Found Of Giant-Plant Eating Dinosaurs
8. Best chance to protect giant pandas
9. Nature reserves arent protecting pandas, study shows
10. Researchers determine genetic cause of Timothy syndrome
11. Rare childhood genetic syndrome identified

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Giant pandas have plenty genetic diversity

(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: